CD4 and myeloid sarcoma: Of the 36 patients with CD4+ T cells <200/ul, 29 (81%) had anti-MS and 28 (77%) had anti-MPT51 antibodies; 31 of 36 (86%) patients tested positive for at-least one of the 2 biomarkers (Fig 3B).